Evotec Signs High Throughput Screening Agreement with Active Biotech
(Thomson Reuters ONE) -
Evotec AG / Evotec Signs High Throughput Screening Agreement with Active Biotech processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - 11 March 2010: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a collaboration with Active
Biotech AB (NASDAQ OMX: ACTI) to identify small molecule modulators of a
priority biological target, selected by Active Biotech, involved in immune
disorders and cancer.
Evotec will use its expertise and technologies in assay development, high
throughput screening (HTS) and surface plasmon resonance (SPR) screening for the
identification and validation of novel hits. In order to maximise the
probability of finding high quality medicinal chemistry starting points, Evotec
will screen its Lead Discovery Library, a small molecule collection designed for
diversity, novelty and quality.
Dorthe da Graça Thrige, Director of Development of Active Biotech, commented:
"We have a high regard for Evotec's expertise and capabilities in assay
development and compound screening. In addition, we are impressed with the
excellent quality of Evotec's Lead Discovery Library, which we believe will
enable us to generate high quality hits, ensuring a smooth transition to
medicinal chemistry activities. Importantly, the hits identified in the HTS will
complement the ongoing lead optimisation of compounds identified in-house."
Dr Mark Ashton, Executive Vice President, Business Development of Evotec stated:
"We are proud to have been selected by Active Biotech, a leading biotechnology
company with advanced drug candidates in the area of immune modulation, to carry
out hit identification activities on this important biological target. We look
forward to supporting them in their quest to find novel treatments to address
immune disorders and cancer."
Evotec has a unique assay development and screening platform built around
proprietary and the latest commercial technologies providing a flexible and high
quality approach to lead identification. Evotec has successfully developed
assays and high throughput screens for all of the major target classes including
GPCR's, kinases and other enzymes, ion channel and protein::protein
interactions.
No financial details are disclosed.
Contact:
Evotec AG
Dr Werner Lanthaler (Chief Executive Officer)
Schnackenburgallee 114
22525 Hamburg
Germany
+49.(0)40.56081-242
werner.lanthaler(at)evotec.com
Active Biotech AB
PO Box 724
SE-220 07 Lund
Sweden
+46 (0)46.19 20 00
+46 (0)46.19 11 00 Fax
Forward-looking statements
Information set forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. Such forward-looking
statements include, but are not limited to, statements about our expectations
and assumptions concerning our strategic collaborations, our regulatory,
clinical and business strategies, the progress of our clinical development
programmes and management's plans, objectives and strategies. These statements
are neither promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which could cause
actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties include,
among other things: risks that product candidates may fail in the clinic or may
not be successfully marketed or manufactured; the risk that we will not achieve
the anticipated benefits of our collaborations, partnerships and acquisitions in
the timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other documents
filed with, or furnished to the Securities and Exchange Commission, contain
additional factors that could impact our businesses and financial performance.
We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on which any
such statement is based.
[HUG#1392805]
--- End of Message ---
Evotec AG
Schnackenburgallee 114 Hamburg Germany
WKN: 566480;ISIN: DE0005664809 ;Index:MIDCAP,HDAX,Prime All Share,CDAX,TECH All Share;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
PDF of Press Release: http://hugin.info/131215/R/1392805/350235.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="CROWFLIGHT RESUMES MILLING OPERATIONS AT BUCKODatum: 11.03.2010 - 02:00 Uhr
Sprache: Deutsch
News-ID 1011224
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Hamburg
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 99 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec Signs High Throughput Screening Agreement with Active Biotech
"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
